Estimated dispatch within 1 to 2 working days subject to receiving a valid prescription.
Zycortal is a new treatment for Addison's disease (hypoadrenocorticism) in dogs. It is given by injection at approximately 1 month intervals. The precise dose and frequency is calculated by your vet in response to blood test results and clinical assessments made durong the initial phases of treatment.
Active substance: Desoxycortone pivalate 25 mg/ml
Excipient: Chlorocresol 1 mg/ml
Prolonged-release suspension for injection. Opaque white suspension.
For use as replacement therapy for mineralocorticoid deficiency in dogs with primary hypoadrenocorticism (Addison's disease).
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Before starting treatment with the veterinary medicinal product, it is important that Addison's disease has been definitively diagnosed. Any dog presenting with severe hypovolaemia, dehydration, pre-renal azotemia and inadequate tissue perfusion (also known as 'Addisonian crisis') must be rehydrated with intravenous fluid (saline) therapy before starting treatment with the veterinary medicinal product.
Use with caution in dogs with congestive heart disease, severe renal disease, primary hepatic failure or oedema.
Avoid contact with the eyes and skin. In case of accidental spillage onto the skin or eyes, wash the affected area with water. If irritation occurs, seek medical advice immediately and show the package leaflet or the label to the physician.
This product may cause pain and swelling at the injection site if accidentally self-administered.
This product may cause adverse effects on male reproductive organs and, as a result, fertility.
This product may cause adverse developmental effects on unborn children and neonates.
Pregnant and breast-feeding women should avoid administration of this product.
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
In a clinical trial, very common adverse reactions were polydipsia and polyuria. Common reactions were inappropriate urination, lethargy, alopecia, panting, vomiting, decreased appetite, anorexia, decreased activity, depression, diarrhoea, polyphagia, shaking, tiredness and urinary tract infections. The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
The safety of the veterinary medicinal product has not been established during breeding, pregnancy or lactation. Therefore, use only according to the benefit:risk assessment by the responsible veterinarian.
Use with caution when administering Zycortal concurrently with medicinal products which affect either serum sodium or potassium concentrations, or cellular transportation of sodium or potassium, for example: trimethoprim, amphotericin B, digoxin or insulin.
Prior to use, gently shake the vial to resuspend the product.
Use an appropriately graduated syringe to accurately administer the required dose volume. This is particularly important when injecting small volumes.
Zycortal replaces the mineralocorticoid hormones only. Dogs with combined glucocorticoid and mineralocorticoid deficiency should also receive a glucocorticoid such as prednisolone in accordance with standard texts.
Zycortal is intended for long term administration at intervals and doses dependent upon individual response. Tailor the dose of Zycortal and the concurrently administered glucocorticoid replacement therapy to the individual dog based on clinical response and normalization of Na+ and K+ serum concentrations.
Initial dose of Zycortal:
The initial dose is 2.2 mg/kg body weight, administered by subcutaneous injection.
Interim monitoring visit:
Re-evaluate the dog and measure the serum sodium/potassium ratio (Na+/K+ ratio) approximately 10 days after the first dose (which is the time to maximum concentration (Tmax) of desoxycortone). If the dog's clinical signs have worsened or not resolved, adjust the dose of glucocorticoid and/or investigate other causes of the clinical signs.
Second dose of Zycortal:
At approximately 25 days after the first dose, re-evaluate the dog and measure the Na+/K+ ratio.
- If the dog is both clinically normal and has a normal Na+/K+ ratio (i.e. 27 to 32) on Day 25, adjust the dose based on the Day 10 Na+/K+ ratio using the guidelines in Table 1, below.
- If the dog is clinically normal and has a Na+/K+ ratio >32 on Day 25, either adjust the dose based on the Day 10 Na+/K+ ratio according to Table 1 or delay the dose (see 'Prolonging the dosing interval').
- If the dog is either not clinically normal or if the Na+/K+ ratio is abnormal on Day 25, adjust the dose of glucocorticoid or Zycortal (see 'Subsequent doses and long term management').
Table 1: Day 25: Administering the Second Dose of Zycortal
If the Day 10 Na+/K+ ratio is:
Dose 2 on
25 days after the first dose, administer Zycortal, as follows:
Decrease dose to: 2.0 mg/kg body weight
32 to <34
Decrease dose to: 2.1 mg/kg body weight
27 to <32
continue 2.2 mg/kg body weight
≥24 to <27
Increase dose to: 2.3 mg/kg body weight
Increase dose to: 2.4 mg/kg body weight
Prolonging the dosing interval:
If the dog is clinically normal and the Day 25 Na+/K+ ratio is >32, it is possible to prolong the dosing interval instead of adjusting the dose as described in Table 1. Evaluate the electrolytes every 5-9 days until the Na+/K+ ratio is <32, and then administer 2.2 mg/kg of Zycortal.
Subsequent doses and long term management:
Once the optimal dose and dosing interval have been determined, maintain the same regimen. If the dog develops abnormal clinical signs or Na+ or K+ ratio serum concentrations, use the following guidelines for subsequent doses:
- Clinical signs of polyuria/polydipsia: Decrease the glucocorticoid dose first. If the polyuria/polydipsia persists and the Na+/K+ ratio is >32, then decrease the dose of Zycortal without changing the dosing interval.
- Clinical signs of depression, lethargy, vomiting, diarrhoea or weakness: Increase the glucocortinoid dose.
- Hyperkalaemia, hyponatremia or Na+/K+ ratio <27: Decrease the Zycortal dosing interval by 2-3 days or increase the dose.
- Hypokalaemia, hypernatremia or Na+/K+ ratio >32: Decrease the Zycortal dose.
Prior to a stressful situation, consider temporarily increasing the dose of glucocorticoid.
In the clinical trial, the mean final dose of desoxycortone pivalate was 1.9 mg/kg (range 1.2-2.5 mg/kg) and the mean final dosing interval was 38.7 ± 12.7 days (range 20-99 days) with the majority of dogs having a dosing interval between 20 and 46 days.
When given to dogs at three to five times the recommended dose, injection site reactions characterised by erythema and oedema occurred.
As expected from the pharmacodynamic effects, escalating doses of desoxycortone are associated with a dose-related trend for increased serum sodium, and decreased blood urea nitrogen, serum potassium and urine specific gravity. Polyuria, polydipsia may be observed.
Hypertension has been observed in dogs receiving 20 mg/kg of desoxycortone pivalate.
There is no specific antidote. In case of signs of overdose, the dog should be treated symptomatically, and subsequent doses reduced.
Pharmacotherapeutic group: Corticosteroids for systemic use, mineralocorticoids
ATC Vet code: QH02AA03
Desoxycortone is a corticosteroid with primarily mineralocorticoid activity, similar to aldosterone. In the kidney, desoxycortone causes sodium and chloride ion retention, and hydrogen and potassium ion excretion, creating an osmotic gradient. The osmotic gradient promotes water absorption from the renal tubules resulting in increased extracellular fluid volume, leading to blood volume expansion, improved venous return to the heart, and increased cardiac output.
After subcutaneous administration of desoxycortone pivalate at a dosage of 11 mg/kg body weight (five times the recommended dosage), the plasma half-life (mean ± standard deviation) is approximately 17 ± 7 days, with a maximum concentration (Cmax) of 13.2 ± 5 ng/ml, and time to maximum concentration (Tmax) of 10 ± 3.5 days.
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.
Shelf life of the veterinary medicinal product as packaged for sale: 3 years
Shelf life after first opening the immediate packaging: 120 days
Do not store above 30°C.
Do not freeze.
Type I glass vial (containing 4 ml) with a coated chlorobutyl rubber stopper and aluminium seal with a plastic flip-off cap.
Pack size of 1.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Dechra Limited, Snaygill Industrial Estate, Keighley Road, Skipton, North Yorkshire, BD23 2RW, United Kingdom.
6 November 2015
For animal treatment only. To be supplied only on veterinary prescription. Keep out of the sight and reach of children.
Zycortal 25 mg/ml prolonged-release suspension for injection for dogs:
All prices include VAT where applicable.
Below are some recent questions we've received regarding Zycortal, including answers from our team.Ask Your Own Question
Sorry that this product is out of stock, instead of having to keep checking back to see if we have it, we can send you a notification as soon as it comes back in stock.
We won't use any details you enter for any other purpose than letting you know when this is back in stock.
Please enter details for each method you'd like us to notify you by:
VioPoints are a way for us to say thank you for purchasing from VioVet.
You will receive VioPoints by purchasing this product, which can be redeemed for a discount on future purchases. For each 1000 points redeemed at the checkout, you will receive a 20p discount.
The number of VioPoints is shown on the product listing and they are awarded on dispatch of the order.
Terms and conditions apply.